RE:RE:RE:New McFarland Labs Research of TLD1433 ProcessesI think it means that they made sure their research doesn't just apply to TLD1433 by also using the PS TLD1633. TLD1633 is TLD1433's younger, more effective and safer brother. McFarland Labs continues ro use it in research even though TLD1433 was preferred for the NMIBC trial. In 2017 TLD1633 was found to be 15X more effective against gbm cells than TLD1433. In 2018 Dr. McFarland explained why TLD1433 was preferred:
"Considering the potency of TLD1633, it may seem odd that TLD1433 was selected instead. TLD1433 was prioritized over the other compound for a number of reasons, including:
(1) there were more synthetic steps required for producing TLD1633, and those steps were low yielding (unoptimized at that time) and required expensive catalysts,
(2) there was more batch-to-batch variability with TLD1633,
(3) the theranostic capacity of TLD1433 was greater (i.e., its luminescence quantum yield was higher), and
(4) we were relatively far along in our pre-clinical studies with TLD1433 by the time the synthesis of TLD1633 was optimized to produce the larger batches required for in vivo studies."
This is just one more example of the vast amount of Dr. McFarland's anti-cancer research Theralase is unable to take advantage of because of a lack of funds.